# Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

> **NCT06824194** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 2360 (actual)

## Conditions studied

- Pneumococcal Immunization

## Interventions

- **BIOLOGICAL:** PCV21 vaccine
- **BIOLOGICAL:** Prevnar 20 vaccine
- **BIOLOGICAL:** M-M-R II vaccine
- **BIOLOGICAL:** Rotarix
- **BIOLOGICAL:** RotaTeq
- **BIOLOGICAL:** Vaxelis vaccine
- **BIOLOGICAL:** Varivax
- **BIOLOGICAL:** Priorix
- **BIOLOGICAL:** VAQTA
- **BIOLOGICAL:** Havrix

## Key facts

- **NCT ID:** NCT06824194
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2027-10-22
- **Final completion:** 2027-10-22
- **Target enrollment:** 2360 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06824194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06824194, "Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06824194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*